8-K: Longeveron Announces 1-for-10 Reverse Stock Split

Longeveron Inc. is implementing a 1-for-10 reverse stock split to boost its share price and comply with Nasdaq listing rules.

Summary

• Longeveron Inc. is executing a 1-for-10 reverse stock split for its Class A and Class B common stock.
• The split is intended to increase the per-share trading price to meet Nasdaq's minimum bid price requirement of $1.00.
• The reverse split was approved by stockholders on July 1, 2026, and by the Board of Directors on July 31, 2026.
• It is expected to become effective on August 26, 2026, with trading on a split-adjusted basis beginning August 27, 2026.
• The company's Class A common stock will trade under the new CUSIP number 54303L 302 and the existing ticker symbol LGVN.
• Approximately 30.4 million shares of Class A common stock will be reduced to about 3.04 million shares.
• Approximately 1.45 million shares of Class B common stock will be reduced to about 144,901 shares.
• Fractional shares will be rounded up to the nearest whole share at the DTC participant level, not at the beneficial ownership level.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a negative development, as it indicates the company is struggling to maintain compliance with listing requirements, suggesting underlying financial or market valuation challenges.

Positives

• Aims to regain compliance with Nasdaq's minimum bid price requirement, potentially avoiding delisting.
• Management believes the structural adjustment will better align the stock with institutional investor preferences.
• The reverse split is described as a structural adjustment that does not change the company's capital-efficient strategy, operations, or the value of stockholders' positions (apart from fractional shares).

Negatives

• The need for a reverse stock split often signals underlying issues with the company's market valuation and financial performance.
• The company is at risk of being delisted from The Nasdaq Capital Market if it does not meet the minimum bid price requirement.
• No cash consideration will be paid to stockholders for fractional shares, and rounding up occurs at the DTC participant level, not the beneficial ownership level.

Risks

• Failure to maintain the minimum bid price requirement for continued listing on The Nasdaq Capital Market.
• Potential difficulties in obtaining access to capital and the dilutive impact of future capital raises.
• The ability of clinical trials to demonstrate safety and efficacy of investigational products.
• Market and other conditions impacting the company's cash position and ability to fund operations.
• The success of competing therapies and the ability to obtain and maintain regulatory approval.

Future Outlook

The company is approaching potentially transformative milestones across its four stem cell therapy development programs and believes the reverse split will better align its share structure with future opportunities and institutional investor preferences.

Management Comments

• "Longeveron Announces 1-for-10 Reverse Stock Split"
• "The 2026 Reverse Split is intended to increase the per share trading price of the Companys Class A common stock to enable the Company to regain compliance with the $1.00 per share minimum bid price requirement for continued listing on The Nasdaq Capital Market."
• "Longeveron is approaching a series of potentially transformative milestones across our four stem cell therapy development programs that have the potential to redefine the trajectory of our business and we believe our share structure should better align with the opportunities we see ahead."
• "This reverse split is a structural adjustment. It does not change our capital efficient strategy, our operations, or the value of any stockholders position apart from adjustments for fractional shares."
• "In addition to supporting our compliance with Nasdaqs continued listing requirements, we believe the 2026 Reverse Split more appropriately aligns our stock with institutional investor preferences, potentially enabling a broader ownership base."

Industry Context

StockSavvy.ai notes that reverse stock splits are a common, albeit often concerning, tactic for companies, particularly in the biotechnology sector, to maintain compliance with exchange listing requirements. This move by Longeveron suggests it is facing pressure to increase its share price, a common challenge for clinical-stage biotechs that often have long development cycles and significant capital needs.

Stakeholder Impact

• Shareholders will see their number of shares reduced by a factor of ten, though the total value of their holdings is intended to remain the same, excluding fractional share adjustments.
• Institutional investors may find the stock more appealing due to the higher per-share price, potentially broadening the ownership base.

Next Steps

• Trading on a split-adjusted basis is expected to commence on August 27, 2026.
• Physical stock certificates will be exchanged for post-reverse split shares through the company's transfer agent.

Key Dates

Recommendation

The reverse stock split is a procedural move to maintain Nasdaq listing, not a reflection of fundamental business improvement. While it addresses a compliance issue, it doesn't inherently change the company's value or prospects. Investors should hold and await further clinical development updates, as the underlying business performance remains the primary driver of long-term value.

Keywords

reverse stock split, Nasdaq compliance, biotechnology, cellular therapy, stock adjustment, listing requirements, common stock, Delaware